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Summary
OBJECTIVE: To describe all patients admitted to chil-
dren’s hospitals in Switzerland with a diagnosis of influ-
enza A/H1N1/09 virus infection during the 2009 influenza
pandemic, and to analyse their characteristics, predictors of
complications, and outcome.
METHODS: All patients ≤18-years-old hospitalised in el-
even children’s hospitals in Switzerland between June 2009
and January 2010 with a positive influenza A/H1N1/09
reverse transcriptase polymerase chain reaction (RT-PCR)
from a nasopharyngeal specimen were included.
RESULTS: There were 326 PCR-confirmed patients of
whom 189 (58%) were younger than 5 years of age, and
126 (38.7%) had one or more pre-existing medical condi-
tion. Fever (median 39.1 °C) was the most common sign
(85.6% of all patients), while feeding problems (p = 0.003)
and febrile seizures (p = 0.016) were significantly more fre-
quent in children under 5 years. In 142 (43.6%) patients
there was clinical suspicion of a concomitant bacterial in-
fection, which was confirmed in 36 patients (11%).
However, severe bacterial infection was observed in 4% of
patients. One third (n = 108, 33.1%) of the patients were
treated with oseltamivir, 64 (59.3%, or 20% overall) with-
in 48 hours of onset of symptoms. Almost half of the pa-
tients (45.1%) received antibiotics for a median of 7 days.
Twenty patients (6.1%) required intensive care, mostly for
complicated pneumonia (50%) without an underlying med-
ical condition. The median duration of hospitalisation was
2 days (range 0–39) for 304 patients. Two children (<15
months of age with underlying disease) died.
CONCLUSIONS: Although pandemic influenza A/H1N1/
09 virus infection in children is mostly mild, it can be
severe, regardless of past history or underlying disease.
Key words: H1N1/09; influenza virus; children;
epidemiology; risk factors; symptoms; hospitalisation;
treatment
Introduction
The pandemic influenza A/H1N1/09 virus (PIA) spread in
the Swiss paediatric population after the first case was dia-
gnosed on April 24, 2009 [1]. However, it was not until
October 2009 that the number of cases and hospitalisation
rates secondary to PIA infection increased notably, reach-
ing a peak in week 49 [1]. In Switzerland, according to
nationally reported data, 5–14-year-old children were the
age group most frequently affected, with 438 cases of con-
firmed PIA infection per 100,000 inhabitants, followed by
0–4-year-old children with 364 cases per 100,000 inhab-
itants [1]. Similarly, in other countries the incidence of
PIA was also highest in children younger than 14 years
[2–4]. This study reviewed all paediatric patients hospital-
ised in children’s hospitals in Switzerland with a diagnos-
is of influenza A/H1N1/09 virus infection during the 2009
influenza pandemic and analyses their characteristics, risk
factors for admission to a paediatric intensive care unit
(PICU), and outcomes.
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Methods
In 2009, Switzerland had an estimated paediatric popula-
tion (≤18 years of age) of 1,542,271 [5]. All children liv-
ing in Switzerland have medical insurance and access to
healthcare. This study was carried out in all 11 children’s
hospitals in the country (comprising the five university
children’s hospitals in Basel, Bern, Geneva, Lausanne and
Zürich, and the children’s hospitals of Aarau, Luzern, St.
Gallen, Hôpitaux du Valais, Fribourg and Triemli in Zurich,
all but the latter three having a paediatric intensive care
unit supplying mechanical ventilation) between June 2009
and January 2010. All patients ≤18 years old, hospitalised
with a positive influenza A/H1N1/09 virus quantitative re-
verse transcriptase polymerase chain reaction (RT-PCR)
from a nasopharyngeal specimen (swab or aspirate), were
included. Demographic and clinical characteristics, labor-
atory and radiological data, treatment, hospital evolution
and outcome were obtained prospectively or retrospect-
ively immediately after the pandemic from medical charts
by use of a uniform, standardised case-report form.
Influenza A/H1N1/09 virus was first detected in April 2009
in Switzerland. The outbreak, however, started on week 44
of 2009 and lasted until week 2 of 2010.
This study was conducted in accordance with the principles
and standards of Good Clinical Practice, with the Helsinki
Declaration, and with the ethics boards’ approval.
Statistical analyses were carried out using SPSS (PASW
Statistics 18.0.0; IBM Corporation, Somers, NY). Standard
descriptive statistics were used to describe demographics,
outcomes and clinical characteristics. Categorical data
were compared with chi-square tests, or Fisher’s exact test
when appropriate. Characteristics of children were com-
pared by using Student’s t-test, linear regression or Mann-
Whitney-U/Kruskal-Wallis tests, according to the type of
independent variable. Multivariate analysis was used to de-
termine predictors of PICU admission. For all statistical
tests, differences were considered significant when p-val-
ues were <0.05.
Results
Three hundred and twenty six PCR-confirmed PIA-pos-
itive children were hospitalised between June 2009 and
January 2010 (median age at admission 43.7 months,
(range 0 to 219.7) in all eleven children’s hospitals in
Switzerland. Rapid antigen tests for influenza were per-
formed at the time in 42 patients (12.9%). Among these,
28 patients (66.7%) had a positive test result. Seventy-
three infants (22%) were <1 year-old and 190 (58.3%) were
male. The peak (87.1%) of PIA-related hospitalisations oc-
curred between November and December 2009. One hun-
dred and twenty-six children (38.7%) had one or more pre-
existing medical condition (table 1), neurological disease
and prematurity (defined as birth at less than 37 weeks
gestational age) being the most frequent conditions.
Vaccination against influenza
Twenty-one children (6.4%) were vaccinated against PIA
before admission, most of them (95%) because of a known
chronic disease, following national recommendations [6].
Table 1: Underlying medical conditions in 126 of 326 Swiss children hospitalised with pandemic influenza A/H1N1/09 virus infection. (>1 condition reported in some
children.)
Pre-existing condition n (%) Vaccinated children
n (%)
Neurological disease * 27 (18.1) 3 (14)
Prematurity 20 (13.4)
Asthma / recurrent wheezing 18 (12.1) 1 (5)
Genetic disease† 10 (6.7 ) 1 (5)
Cancer¶ 9 (6) 3 (14)
Chronic lung disease§ 7 (4.7) 4 (19)
Cardiovascular disease‡ 6 (4) 2 (10)
Inborn errors of metabolism** 6 (4) 1 (5)
Sickle cell disease 5 (3.4) 1 (5)
Renal disease†† 5 (3.4)
Diabetes mellitus 4 (2.7)
Haematological disease¶¶ 4 (2.7) 1 (5)
Immunodeficiency§§ 4 (2.7) 1 (5)
Crohn’s disease 2 (1.3)
Other‡‡ 22 (14.8) 2 (10)
No comorbidities 1 (5)
Total 149 (100) 21 (100)
* Seizures/epilepsy n = 9; recurrent febrile seizures n = 3.
† Down’s syndrome n = 2.
¶ Leukaemia n = 5.
§ Cystic fibrosis n = 4.
‡ Primary pulmonary hypertension n = 2, heart transplantation n = 1.
** Mitochondrial disorder, citrullinaemia, tyrosinaemia, leucinosis.
†† Renal transplantation n = 1.
¶¶ Bone marrow transplantation (other than cancer) n = 2.
§§ Asplenia, mannose binding lectin deficiency, hypogammaglobulinaemia, congenital human immunodeficiency virus infection.
‡‡ Stevens-Johnson syndrome, Kawasaki disease, Addison’s disease, chronic recurrent multifocal osteomyelitis, severe burns, portal vein thrombosis, transitory synovitis
of the hip.
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Only two patients were vaccinated twice. Eighteen patients
were vaccinated 1–54 days (median 7, interquartile range
[IQR] 12) before onset of disease; two patients were vac-
cinated 3 and 4 days after the onset of symptoms (missing
data for one patient).
Hospital admission
Hospital admission was at a median of 2 days (range 0–39,
IQR 4) after the beginning of illness in 308 patients (15
patients were already hospitalised, missing data for 3 pa-
tients). Reasons for hospital admission are summarised in
table 2: >80% of children were admitted with a respiratory
tract infection, febrile seizures, or vomiting/dehydration. In
the initial stages of illness, respiratory symptoms alone ap-
peared a median of 4 days (range 0–25, IQR 4) before ad-
mission in 170 patients.
Admission to intensive care unit
Twenty (6.1%) of 326 patients were admitted to the PICU.
Of these, six (30%) were 0–4 years of age including three
<12 months; eight (40%) were 5–11 years old and six
(30%) were 12–18 years old. Older children (12–18 years
old) had proportionately a higher likelihood to be admitted
to the PICU than the younger age groups (12.2% vs 0–4
[3.2%] and 5–11 years old [9.1%], p = 0.025), but they also
had more comorbidities (61.2% vs 42.2% and 21.3%, re-
spectively, p <0.001). The main reason for PICU admission
was complicated pneumonia (n = 10, 50%). Six (30%) pa-
tients required mechanical ventilation. The median stay in
the PICU was 3 days (range 1–21, IQR 4). In the multivari-
ate analysis, only older age group was a predictor of PICU
admission.
Hospital stay and death
The median duration of hospitalisation was 2 days (range
0–36, IQR 3) for 304 patients (excluding 15 patients with
nosocomial influenza), and data were missing for seven
foreign patients who were transferred back to hospitals in
their home countries.
Among the 326 hospitalised children, two (0.6%) died
which results in a mortality of 0.13 per 100,000 children.
One was a 5-month-old boy with an unknown syndrome
who died after a cardiac arrest and was declared dead on
arrival in the hospital. On autopsy, bacterial pneumonia
was found as cause of death. The second patient was a
15-month-old girl with a history of pre-B acute lymph-
oblastic leukaemia. She was admitted because of febrile
neutropenia and pneumonia on the day of onset of symp-
toms, and died from cardiorespiratory failure 8 days later
Clinical presentation
Signs and symptoms during hospital stay are described in
table 3. Fever was the most common sign (median 39.1 °C,
IQR 0.8), present in 85.6% of all patients. Feeding prob-
lems, febrile seizures, and conjunctivitis were significantly
more frequent in children <5 years old compared with older
age groups.
Chest radiography was performed in 136 patients, and was
normal in 25 children (18.4%). The remaining 111 patients
had one or more of the following abnormal findings:
peribronchial or perihilar (n = 51; 37.5%), lobar (n = 48;
35.3%), or multilobar (n = 21; 15.4%) infiltrates, pleural
effusion (n = 16; 11.8%), atelectasis (n = 15; 11%), and in-
terstitial infiltrates (n = 14; 10.3%). Thus, 85 of 136 pa-
tients (62.5%) had radiological signs of pneumonia. Oxy-
gen supplementation was required in 79 patients (24.2%),
mostly in patients <5 years old (48/79; 60.8%), a third be-
ing less than 12 months of age (18 of 48; 37.5%).
Among all hospitalised patients, 142 (43.6%) had suspec-
ted bacterial infection (based on clinical, biological, or
radiological evaluation by the physician in charge and
prompting antibiotic treatment), including severe bacterial
infections, such as sepsis or septic shock (n = 7), toxic
shock syndrome (n = 3), meningitis (n = 1), mastoiditis (n
= 1), or bacterial peritonitis (n = 1). Pneumonia on chest ra-
diography was diagnosed in 85 patients: four children de-
veloped pleural effusion and one had empyema. Three chil-
dren had a complicated necrotising pneumonia secondary
Table 2: Reasons for hospitalisation of 326 children with laboratory-proven pandemic influenza A/H1N1/09 virus (PIA) infection.
Admission diagnosis n (%)
Related to PIA infection 279 (85.6)
Respiratory tract infection
Bronchiolitis
163 (61.1)
12 (3.7)
Febrile seizure 35 (13.1)
Gastroenteritis/vomiting/dehydration 19 (7.1)
Nonfebrile seizures / epilepsy 12 (4.5)
Severe influenza-like illness
Associated bacterial infection
10 (3.8)
12 (3.7)
Neurological problem* 8 (3)
Feeding problem 7 (2.6)
Social problem 5 (1.9)
Neutropenia 3 (1.1)
Vaso-occlusive crisis (sickle cell) 2 (0.7)
Other 3 (1.1)
Associated with PIA infection 47 (14.4)
Nosocomial PIA infection 15 (4.6)
Risk for complications secondary to PIA infection due to underlying disease 10 (3.1)
Others† 22 (6.7)
* Encephalitis, meningitis signs, facial palsy.
† Surgical procedures, trauma, idiopathic thrombocytopenic purpura, Stevens-Johnson syndrome, diabetic ketoacidosis, inborn errors of metabolism.
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to Staphylococcus aureus (n = 1) or Streptococcus pneumo-
niae (n = 2) infection. Four patients had a clinical diagnosis
of atypical pneumonia. Secondary bacterial infection was
microbiologically proven in 36 (25.4%) of 142 patients
with suspected bacterial infection, which corresponds to
11% of all patients hospitalised with PIA infection. The
most frequently isolated bacteria were S. pneumoniae (n =
10) and S. aureus (n = 5). Children with secondary bacteri-
al infection were significantly older than those without (86
vs 61 months, p = 0.018), but gender distribution was not
different between groups.
Treatment
Antibiotics were prescribed in 147 patients (45.1%), most
commonly amoxicillin with clavulanic acid (n = 61), amox-
icillin (n = 24), and ceftriaxone (n = 21). Combination anti-
microbial therapy was used in 14 patients, usually compris-
ing a third generation cephalosporin with an aminoglyc-
oside (n = 7). The main reason for antibiotic use was a
respiratory tract infection, in particular suspected bacterial
pneumonia. In three patients, antibiotics were reported as
prescribed prophylactically. The median duration of antibi-
otic treatment was 7 days (range 1–35, IQR 5).
Oseltamivir was prescribed in 108 patients (33.1%), for
a median duration of 5 days (range 2–10, IQR 0). In 64
(59.3%) of these patients oseltamivir was administered
within 48 hours of onset of symptoms. Median duration
of hospitalisation in these 64 children was 2.5 days (range
1–63, IQR 3), while it was 2 days for the children receiving
oseltamivir after 48 hours (p = 0.064). Median duration
of hospitalisation for children not treated with oseltamivir
was 3.4 days (range 0–32). Among 64 oseltamivir-treated
patients before 48 hours, 32 (50%) were <5 years of age
and 39 (60.9%) patients had a pre-existing medical condi-
tion. Pneumonia was observed in 7 (10.9%) of 64 patients
treated with oseltamivir within 48 hours, and in 78 (29.8%)
of 262 not treated with oseltamivir or treated >48 hours
after onset of disease (p <0.001). Four (6.2%) of 64 chil-
dren treated with oseltamivir within 48 hours were admit-
ted to the paediatric intensive care unit (PICU), where two
of them required mechanical ventilation. The use of os-
eltamivir did not decrease the risk of admission to the PICU
(odds ratio 1.025; 95% confidence interval 0.331 to 3.178).
Discussion
This study describes all children admitted to paediatric hos-
pitals in Switzerland with confirmed influenza A/H1N1/
09 disease during the 2009 influenza pandemic. Most of
the children were less than 5 years old and a significant
proportion of patients were younger than 1 year of age,
both findings being similar to the previous influenza season
(2008/2009) in Switzerland [7]. According to the national
database, the hospitalisation rate for pandemic influenza
in Switzerland was 72 per 1,000 confirmed cases in the
0–4 years age group or 26 per 100,000 children 0–4 years
of age, which was the highest after the >65 years-old group
[1].
In our study, the calculated incidence was almost twice as
much, i.e. 49/100,000 (189 of 382,170 children 0–4 years
of age living in Switzerland at the end of the year 2009;
http://www.bfs.admin.ch/bfs/portal/de/index/themen/
01.html). This discrepancy indicates that underreporting of
cases through the national pandemic influenza surveillance
system had occurred.
Time between onset of disease and hospital admission was
unusually short. This may be related to the virulence of this
particular pandemic influenza virus and/or increased me-
dia attention that might have caused fear, not only amongst
parents but also amongst healthcare workers leading to rap-
id hospitalisations.
Table 3: Signs and symptoms before or during hospital stay in 326 children with laboratory-proven influenza A/H1N1/09 virus infection, by age group.
Age group in years (%)* p-value Total (%)†
0‒4
189
58%
5‒11
88
27%
12‒18
49
15%
326
n (%) n (%) n (%) n (%) n (%)
Fever ≥38 °C 163 (86.2) 75 (85.2) 41 (85.4) NS 279 (85.6)
Cough 154 (81.5) 71 (80.7) 39 (79.6) NS 264 (81)
Rhinitis 149 (78.8) 57 (64.7) 32 (65.3) NS 238 (73)
Pharyngitis 60 (31.7) 40 (45.5) 19 (38.8) NS 119 (36.5)
Feeding problems 82 (43.4) 20 (22.7) 13 (26.5) 0.003 115 (35.3)
Vomiting 53 (28.0) 25 (28.4) 15 (30.6) NS 93 (28.5)
Dyspnoea 50 (26.5) 25 (28.4) 16 (32.7) NS 91 (27.9)
Wheezing 45 (23.8) 25 (28.4) 11 (22.4) NS 81 (24.8)
Diarrhoea 44 (23.3) 13 (14.7) 5 (10.2) NS 62 (19)
Conjunctivitis 16 (84.7) 11 (12.5) 0 (0) 0.022 27 (8.3)
Exanthema 7 (3.7) 8 (9.1) 5 (10.2) NS 20 (6.1)
Hoarseness 9 (4.8) 7 (8.0) 1 (2.0) NS 17 (5.2)
Croup-like coughing 8 (4.2) 5 (5.7) 2 (4.1) NS 15 (4.6)
Pneumonia 43 (22.8) 29 (33.0) 12 (24.5) NS 84 (25.8)
Febrile seizures 35 (18.5) 11 (12.5) 1 (2.0) 0.016 47 (14.4)
Otitis media 22 (11.6) 4 (4.5) 1 (2.0) NS 27 (8.3)
Bronchiolitis 10 (5.3) 1 (1.1) 1 (1.7) NS 12 (3.7)
* Within sign or symptom.
† Within total of patients.
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Approximately one-third of hospitalised children in our
study had an underlying medical condition. This is compar-
able to other paediatric studies, which reported an underly-
ing condition as a risk factor for hospital admission in 32%
to 75% of patients during the same pandemic [8–14]. As in
other studies, the main cause for hospitalisation was respir-
atory tract disease, followed by gastrointestinal symptoms
in all age groups [9, 10, 12]. Asthma was identified by oth-
ers as a major risk factor for admission in the PICU [8].
In our study, only 12% of hospitalised children had asthma
and only one patient was admitted to the PICU.
Influenza is known to cause febrile seizures in children
[15]. Most of the patients admitted with febrile seizures
in our study did not have a prior history of neurological
disease. However, the true incidence of febrile seizures in
children with pandemic influenza A/H1N1/09 virus infec-
tion is difficult to assess, because children with uncomplic-
ated febrile seizures are often not admitted to hospital [16].
We observed an unusually high proportion of severe bac-
terial co-infections, which does not concur with other pae-
diatric reports describing much lower rates (<5%) [8, 12,
17]. This could be explained by the fact that bacterial co-in-
fection was actively searched for in most patients, because
of the notion that influenza-associated paediatric mortal-
ity is usually linked with bacterial co-infection [18, 19].
As a consequence, almost 50% of our patients were ini-
tially treated with antibiotics. The design of this study pre-
vents us from establishing if this high use of antibiotics
had an impact on disease outcome. However, the paediatric
mortality rate secondary to PIA infection during the 2009
influenza pandemic in Switzerland was low and the two
fatalities that occurred were in children with severe under-
lying medical conditions. The relatively small number of
patients admitted to PICU is probably explained by the fact
that the pandemic overall was less severe than anticipated
and access to healthcare is easy in Switzerland, leading to
rapid interventions. In our study, only older age (12–18
years old) was a predictor of PICU admission. However,
it should be noted that comorbidity was also significantly
higher in children hospitalised in this age group. Interest-
ingly, children admitted to PICU with complicated pneu-
monia had no pre-existing conditions, such as immunosup-
pression or chronic lung disease.
Oseltamivir was prescribed in approximately one-third of
our patients and in a little more than half of the patients this
was done within the recommended time frame, i.e. within
48 hours of onset of symptoms. It may seem surprising that
such a low percentage of children were treated although of-
ficial recommendations called for treatment of all hospital-
ised children. It is likely that Swiss paediatricians hesitated
to treat with oseltamivir because of early reports from the
southern hemisphere about the small effect of oseltamivir
on symptoms and on transmission [20, 21]. Similarly, in
our study oseltamivir treatment did not appear to reduce the
risk of PICU admission. However, the number of patients
admitted was low and this may reflect a lack of power of
our study.
Vaccinating children ≥6 months of age against influenza
and taking advantage of indirect protection of young chil-
dren by vaccinating their parents and other household
members could have had a significant effect in decreasing
hospitalisation rates among infants. Early in the course of
the pandemic, the Swiss Federal Committee for Vaccin-
ations had recommended that children ≥6 months of age
with underlying disease should be vaccinated with pan-
demic influenza vaccine as soon as possible [6]. However,
because of the belated authorisation by the Swiss regulat-
ory agency, only a small percentage of children at risk were
immunised before the pandemic reached its peak. This ex-
plains the low number of vaccinated children and the short
period between vaccination and illness in several patients.
Influenza vaccination rates in children in Switzerland are
unfortunately unavailable for this period.
Our study has several limitations. First, it was not per-
formed prospectively in all centres. However, all data was
retrieved from the medical charts less than 6 months after
hospital admission by paediatric infectious disease spe-
cialists using a standardised case-report form. Second, al-
though the setting included all paediatric hospitals in
Switzerland we cannot exclude the possibility that paedi-
atric patients with influenza, especially adolescents, were
admitted to medical centres for adults. Nevertheless, it is
likely that the most severe cases and those with longer
hospital stays would have been transferred to a children’s
hospital rapidly after admission. Finally, because the cases
in the paediatric community were not reported system-
atically, predictors of hospitalisation could not be evalu-
ated. However, although there were similar results to those
of previous studies, confirming the clinical aspects of the
disease [8–12, 17], we show that pandemic influenza
A/H1N1/09 virus infection in children can be associated
with increased disease severity regardless of past history
or underlying disease, even in the young age group, as has
been shown for seasonal influenza [22].
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